Topical corticosteroid foam vehicle offers comparable coverage compared with traditional vehicles

Journal of the American Academy of Dermatology

Volumn 42, Issue 6, 2000, Pages 1017-1020

  Feldman, Steven R ^a,b   Sangha, Namrata ^a   Setaluri, Vijay ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b Bradley Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE VALERATE; CORTICOSTEROID; DRUG VEHICLE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; FOAM; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSORIASIS;

EID: 0034039616     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2000.104892     Document Type: Article

References (6)

1. Feldman SR. Psoriasis treatment. Curr Probl Dermatol 1998;10: 1-40.
2. Rapp SR, Exum ML, Reboussin DM, Feldman SR, Fleischer A, Clark A. The physical, psychological and social impact of psoriasis. J Health Psychol 1997;2:525-37.
3. Crutchfield CE III, Lewis EJ, Zelickson BD. The highly effective use of topical zinc pyrithione in the treatment of psoriasis: a case report. Dermatol Online J 1997;3. http://matrix.ucdavis. edu/DOJvol3num1/zinc/zinc/html.
4. Franz T. Phase III trial results with betamethasone valerate foam versus betamethasone valerate solution. Int J Dermatol In press.
5. Long CC, Finlay AY. The finger-tip unit: a new practical measure. Clin Exp Dermatol 1991;16:444-7.
6. Schlagel CA, Sanborn EC. The weights of topical preparations required for total and partial body inunction. J Invest Dermatol 1964;42:253-6.